• CK2-Dependent Stabilization of ECE-1c Drives Lung Cancer Agg

  2026-07-01

  This study establishes a mechanistic link between CK2-mediated stabilization of endothelin-converting enzyme-1c (ECE-1c) and the acquisition of cancer stem cell-like traits, chemoresistance, and invasiveness in non–small cell lung cancer. The findings position phospho-ECE-1c as a prognostic marker and underscore the therapeutic potential of CK2 inhibition strategies, such as Silmitasertib, in targeting aggressive lung cancer phenotypes.

• 3X (DYKDDDDK) Peptide: Benchmarking Affinity and Detection

  2026-06-30

  The 3X (DYKDDDDK) Peptide enables high-sensitivity affinity purification and immunodetection of FLAG-tagged recombinant proteins. Its trimeric hydrophilic sequence improves antibody binding and protocol flexibility, making it a robust tool for molecular biology and protein crystallization workflows.

• Neuromedin S (rat): Technical Guidance for GPCR Signaling St

  2026-06-30

  Neuromedin S (rat) is a chemically defined, endogenous peptide agonist for controlled activation of neuromedin U receptor signaling in rat-based GPCR/G protein research. It is intended for reproducible in vitro and ex vivo workflows investigating pathways such as energy homeostasis regulation and stress response, but is not suitable for diagnostic, therapeutic, or in vivo clinical applications.

• Bortezomib (PS-341) Applied Workflows: Optimizing Apoptosis

  2026-06-29

  Bortezomib (PS-341) is a gold-standard proteasome inhibitor, enabling precise interrogation of apoptosis and proteostasis in cancer and beyond. This article delivers actionable protocols, troubleshooting strategies, and highlights workflow innovations, empowering researchers to maximize reliability and biological insight using APExBIO's trusted reagent.

• Y-27632 Dihydrochloride: Precision Tools for Organoid and St

  2026-06-29

  Explore how Y-27632 dihydrochloride, a primary ROCK inhibitor, is reshaping advanced stem cell and organoid research. This article uniquely connects molecular mechanism, protocol precision, and translational cartilage modeling for next-generation applications.

• SU6656 Src Tyrosine Kinases Inhibitor: Protocols & Platelet

  2026-06-28

  SU6656, a potent Src tyrosine kinases inhibitor from APExBIO, is redefining workflows in both ex vivo platelet production and translational oncology. By integrating small molecule modulation with optimized protocols, researchers can streamline megakaryocyte polyploidization and enhance radiotherapy outcomes—delivering proven efficiency gains and new experimental possibilities.

• FAST: Food-Grade Nanoparticles for Enhanced Nutraceutical De

  2026-06-27

  The referenced study introduces Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade method for producing stable, highly bioavailable nutraceutical nanoparticles. This innovation addresses solubility and biocompatibility barriers with clean-label, scalable processes, enabling next-generation oral supplement delivery.

• Oligo (dT) 25 Beads: Technical Guide for Eukaryotic mRNA Iso

  2026-06-26

  Oligo (dT) 25 Beads are designed for rapid, high-purity isolation of eukaryotic mRNA by selectively binding polyA tails. They are appropriate for workflows such as RT-PCR, cDNA synthesis, and sequencing, but are not suited for non-polyadenylated or prokaryotic RNA samples. Their use improves workflow efficiency and RNA integrity where polyA tail capture is essential.

• ABT-737 in Mitochondrial Apoptosis: Deep Mechanisms & Resear

  2026-06-26

  Explore how ABT-737, a leading BCL-2 protein inhibitor, drives apoptosis induction in cancer cells via mitochondrial pathways. This article unveils novel mechanistic insights, integrating recent mitophagy research and practical assay guidance.

• AT-406 (SM-406): Optimized Apoptosis Activation in Cancer Re

  2026-06-25

  AT-406 (SM-406) empowers researchers with precision control over apoptosis pathway activation in cancer cells, offering robust sensitization to chemotherapy and reproducible results in both in vitro and in vivo models. This guide delivers actionable protocols, troubleshooting strategies, and insights from recent structural biology to elevate oncology workflows.

• Epigenetic Silencing Drives Heterogeneity in Synthetic Circu

  2026-06-25

  This article examines a study that reveals how epigenetic silencing, not sequence changes, underlies expression variability in multi-transcript unit genetic circuits integrated into mammalian genomes. The research demonstrates that chromatin state, particularly accessibility and epigenetic modifications, dictate the stability and function of complex synthetic constructs, with implications for synthetic biology and gene therapy.

• Hematoxylin and Eosin Staining Kit: Technical Workflow Guide

  2026-06-24

  The Hematoxylin and Eosin Staining Kit (SKU: K1142) provides ready-to-use solutions for consistent histopathological and cytological tissue staining, ensuring reliable cellular and tissue morphology visualization in paraffin and frozen sections. This kit is for research use only and should not be used in clinical diagnosis or medical testing.

• TRIM66 as an Epigenetic Gatekeeper of Olfactory Receptor Cho

  2026-06-23

  The reference study reveals TRIM66 as a central epigenetic repressor that enforces the 'one neuron-one receptor' rule in olfactory sensory neurons. This discovery clarifies the molecular mechanism behind monogenic olfactory receptor expression and has broad implications for understanding sensory coding and gene regulation.

• Applied Workflows with Novobiocin Sodium: DNA and Pathway In

  2026-06-23

  Novobiocin Sodium, a potent aminocoumarin antibiotic, is revolutionizing DNA damage, metabolic enzyme, and apoptosis pathway research due to its unique DNA gyrase inhibition. This article translates cutting-edge findings from anti-parasitic assays and cell-based workflows into actionable protocols, troubleshooting advice, and comparative analysis for researchers seeking superior control over DNA replication and cellular signaling.

• Novel HER2 Inhibitors Target EMT in Breast Cancer: Insights

  2026-06-22

  This study introduces a new class of HER2 inhibitors engineered from a Mubritinib-derived scaffold, with enhanced anti-breast cancer activity mediated through inhibition of the epithelial-mesenchymal transition (EMT) pathway. The findings highlight the promise of structure-guided design for improving HER2 signaling pathway inhibition and provide a comparative perspective on established inhibitors.

454 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page